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Introduction
Thanks to improvements in screening programs, cervical 
cancer is more frequently diagnosed in early stage of 
disease [1]. Although the International Federation of 
Gynecology and Obstetrics (FIGO) staging system does 
not include lymph node (LN) status [2], presence of lymph 
node metastasis (LNM) is considered the most important 
prognostic factor [3–5] in cervical cancer patients.
Traditionally, to obtain histological diagnosis of nodal 
spread, all pelvic LNs are removed. However, pelvic/aortic 
lymphadenectomy (LND) is associated with short- and 
long- term morbidities, such as prolonged duration of 
surgery, increased blood loss, infection, nerve and vascular 
injury, venous thromboembolism, lymphocyst formation, 
and lower extremity lymphedema [6–9]. In an effort to 
decrease complications associated with “unnecessary” LND 
and, at the same time, to assess LN status, sentinel lymph 
node (SLN) biopsy technique has been developed and 
investigated by multiple groups with encouraging data in 
terms of sensitivity and negative predictive value (NPV) 
[10–12]. The idea of using sentinel node biopsy is based 
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Abstract
Nowadays cervical cancer is frequently diagnosed at early stage. For these  patients 
lymph node metastasis (LNM) is considered the most important prognostic 
factor. During the last decade many efforts have been made to reduce rate of 
complications associated with lymphadenectomy (LND). A great interest has 
arisen in sentinel lymph node (SLN) biopsy as a technique able to decrease 
number of LND performed and, at the same time, to assess lymph nodal status. 
High diagnostic performances have been reached thanks to SLN surgical algo-
rithm. However, despite the efforts, about 25% of these patients undergo at 
least unilateral LND to meet NCCN recommendations. Data of women with 
International Federation of Gynecology and Obstetrics stage IA1- IB1/IIA1 cervi-
cal carcinoma were retrospectively collected by six Italian institutions. All patients 
underwent complete preoperative staging workup and were primarily treated 
by radical hysterectomy and pelvic bilateral LND. A total of 368 patients with 
early- stage cervical cancer were identified. Among them 333 (90.5%) showed 
no suspicious enlarged nodes at the preoperative magnetic resonance imaging 
(MRI). In this subset, tumor diameter ≥20 mm was the only independent pre-
dictor of LN status (P = 0.003). None of the 106 patients with negative MRI 
nodal assessment, with squamous and adenosquamous histotype and a tumor 
diameter less than 2 cm had LNM. Based on these results we propose a new 
modified SLN surgical algorithm that could safely reduce LND performed in 
patients with very low- risk early- stage cervical cancer.
Cancer Medicine
Open Access
1726 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
A. Fagotti et al.Until Avoiding Pelvic Lymphadenectomy
on the fact that status of regional LNs could be accurately 
represented by the status of the SLN. However, regardless 
of the technique used, detection rate of SLN ranges from 
92% to 97% of overall mapping to 70–79% of complete, 
bilateral, mapping [13, 14]. In order to ensure the detec-
tion of all LNM, an algorithm that recommends side- 
specific nodal dissection in case of failed SLN mapping 
and removal of all suspicious enlarged nodes was developed 
and introduced in international guidelines [15, 16]. In 
this algorithm, at least 25% of patients with early- stage 
cervical cancer still undergo pelvic LND, with no data 
reported on their metastatic rate until now.
The objective of this study was to identify a subgroup 
of patients in whom it is possible to avoid unnecessary 
systematic LND, either in case of failed SLN mapping, 
or regardless of SLN mapping.
Patients and Methods
This is a retrospective, multicenter study. Data for the cur-
rent analysis were provided from six different Italian insti-
tutions (Catholic University of the Sacred Heart–Rome; 
Foundation for Research and Care “Giovanni Paolo II”–
Campobasso; “Regina Elena” National Cancer Institute–
Rome; “Sant’Orsola- Malpighi” Hospital–Bologna; St Maria 
Hospital–Terni; University East Piedmont “A. Avogadro”–
Novara). Institutional review board approval was obtained 
from each Center. All women included in the study had 
a proved diagnosis FIGO stage IA1- IB1/IIA1 cervical car-
cinoma with negative LNs assessment at preoperative imaging 
by magnetic resonance imaging (MRI). Patients undergoing 
neo- adjuvant therapy before surgery were excluded.
All cases were primarily treated by radical hysterectomy 
and systematic pelvic bilateral LND [17]. No patient 
received SLN biopsy during the study period. Para- aortic 
LND was performed at attending discretion and, anyhow, 
if pelvic LNs were found to be positive at frozen section 
analysis. Dedicated pathologists at each center performed 
histological diagnosis. Adjuvant treatment was suggested 
according to NCCN guidelines [18]. Imaging assessment 
by FDG- PET/CT, CT scan, or MRI was done at comple-
tion of adjuvant treatment. Women were followed up 
and monitored by clinical examination every 3 months 
for 2 years, every 6 months for 3 years, then annually 
until death. During follow up, the need for imaging was 
triggered by clinical symptoms. Disease progression was 
defined according to NCCN criteria [18].
Patient demographics, medical, surgical, pathological, 
and follow- up data were retrospectively collected inde-
pendently by each institution and subsequently collected 
together in an electronic database.
All statistical calculations were performed by SPSS soft-
ware, version 17.0 (SPSS, Chicago, IL).
Results
From February 2000 to March 2015, 368 patients with 
early- stage cervical cancer were identified. Among them, 
333 met inclusion criteria and were included in the analysis 
(Table 1). Median age was 46 years (range 25–76) and 
median body mass index was 23.5 kg/m2 (range 17–51). 
Majority of patients were diagnosed as having squamous 
carcinoma at FIGO stage IB1 (289/333, 86.8%). Type of 
radical hysterectomy was classified according to Querleu 
and Morrow [17] and distributed as follows: 17 (5.1%) 
type A, 161 (48.3%) type B, and 155 (46.6%) type C. 
Surgery was performed by Minimally invasive surgery 
(MIS) (either laparoscopy or robotics) in 143 cases (42.9%). 
All patients received pelvic LND, and a median of 28 
(range 14–80) pelvic LNs was registered. Thirty- two women 
(9.6%) had positive pelvic nodes at definitive histology, 
with a MRI NPV of 90%. Thirty- seven patients underwent 
aortic LND, with a median of 14 (range 2–37) LNs 
removed. Among them, four (10.8%) patients were found 
as having aortic LNM. One hundred and fourteen patients 
(34.4%) underwent adjuvant therapy: 52 (45.4%) received 
chemo- radiation, 56 (49.3%) radiotherapy alone, and six 
(5.2%) chemotherapy alone. The median follow up was 
37 months (range 10–158). Five years progression- free 
Table 1. Demographic and clinicopathologic characteristics of all 
patients.
Characteristics Patients, n (%)
All 333
Median age (years) (range) 46 (25–76)
Median BMI (kg/m2) (range) 24 (17–51)
Median tumor diameter (mm) (range) 17 (1–40)
FIGO stage
IA 1/2 41 (12.3)
IB 1 289 (86.8)
IIA 1 3 (0.9)
Histology
Squamous carcinoma 229 (68.8)
Adenocarcinoma 81 (24.3)
Adenosquamous 15 (4.5)
Clear cell 4 (1.2)
Other 4 (1.2)
Grading
1 29 (8.8)
2 152 (45.6)
3 152 (45.6)
Median no. pelvic LNs removed (range) 28 (14–80)
No. of cases with positive pelvic LNs 32 (9.6)
No. of cases submitted to aortic LND 37 (11.1)
Median no. aortic LNs removed (range) 14 (2–37)
No. of cases with positive aortic LNs 4 (10.8)
BMI, body mass index; FIGO, International Federation of Gynecology 
and Obstetrics; LNs, lymph nodes; LND, lymphadenectomy.
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survival (PFS) and overall survival (OS) rates were 92.5% 
and 95.6%, respectively, in the entire population.
Table 2 shows the distribution of LN metastases accord-
ing to patient and tumor characteristics. At multivariate 
analysis tumor diameter ≥20 mm was the only independent 
predictor of LN status in this patient population. 
Interestingly, among patients with tumor volume less than 
2 cm, only one (0.7%) woman had LNM. She was a 
49- year- old woman with a G2 adenocarcinoma and a tumor 
diameter of 17 mm having metastasis in two pelvic LNs.
Therefore, the combination of histopathological char-
acteristics (squamous and adenosquamous histotype) and 
tumor diameter less than 2 cm along with preoperative 
MRI nodal assessment allowed to reach a NPV of 100%, 
with respect to the risk of unexpected LNM. This group 
of women was named very low- risk group (VLRG), as no 
LNM was found among 106 patients meeting inclusion 
criteria. In the VLRG, 14 women (13.2%) received adjuvant 
radiotherapy, based on histopathological risk factors [18]. 
With a median follow up of 40 months (16–158), seven 
(6.6%) recurrences have been registered: five central pelvic 
(one with LNs) and two distant metastases. None had 
exclusive lymphnodal recurrence. Among those patients 
who recurred in the VLRG, two women had multiple risk 
factors at definitive histological diagnosis (G3, deep stromal 
invasion, and/or lymphovascular space invasion), requiring 
adjuvant treatment. However, they did not receive radio-
therapy due to the presence of large infected lymphocele 
and sepsis in one case and refusal in the other one. No 
risk factors were observed in the remaining five cases. The 
rate of relapse in the no- VLRG was 8.8% (20 of 227) and 
no statistically significant difference was registered between 
the groups (VLRG vs. no- VLRG recurrence rate P = 0.32).
Figure 1 shows PFS and OS in the VLRG and no- VLRG. 
As expected, survival outcomes are better in the VLRG 
versus no- VLRG (5- year PFS rate 93.4% vs. 92.1%; 
P = 0.37 and 5- year OS rate 97.2% vs. 94.8%; P = 0.15), 
but no statistically significant difference was reached.
Conclusions
Despite large studies have demonstrated a good diagnostic 
performance of SLN biopsy in cervical cancer patients, 
with a NPV ranging from 94.3% to 98.2%, one of the 
main concerns about its full adoption is the relatively 
low detection rate of the technique [11, 13, 19–22]. As 
a matter of fact, looking at the official international lit-
erature, the frequency of a correct SLN identification really 
varies from one approach used to another and from a 
working team to another. In this context of very hetero-
geneous data, referring to the French and American studies 
that report the best results, the chance of optimal SLN 
identification is not superior to 76.5% [13, 15]. These 
results significantly impact the overall sensitivity of the 
procedure, as a failure in SLN mapping in one or both 
the hemipelvis leaves the “negative” side completely unin-
vestigated. To improve sensitivity and NPV of the SLN 
technique up to 100%, and to reduce the false- negative 
rate to 0%, a side- specific nodal dissection has been intro-
duced in any case of failed SLN mapping [15]. In other 
words, if the best bilateral SLN detection rate reported 
in literature is about 75%, one quarter of women with early- 
stage cervical cancer need to undergo at least unilateral 
LND to meet NCCN algorithm recommendations.
With the aim to increase the number of women to 
spare unnecessary pelvic LND, here we identified a sub-
group of cervical cancer patient at very low risk (VLR) 
of LNM. We interestingly found that no patient, with 
negative MRI nodal assessment, with squamous and aden-
osquamous histotype and a tumor diameter less than 2 cm 
had LNM. This finding is consistent with previously 
reported data suggesting that squamous cervical cancer 
less than 2 cm in size has a LNM incidence ranging from 
0% to 6% [23, 24]. It is also worth noting that both 
histotype and tumor volume can be easily obtained 
Table 2. Clinicopathologic factors related to LNM.1
Analysis
Factor
LNM Univariate Multivariate
No Yes P- value2 P- value3
Age
<46 141 16
≥46 160 16 0.438 –
FIGO stage
IA 1/2 41 0
IB 1 258 31
IIA 1 2 1 0.035 0.153
Histology
Squamous 
carcinoma
209 20
Adenocarcinoma 74 7
Adenosquamous 11 4
Clear cell 3 1
Other 4 0 0.145 –
Grading
1 29 0
2 140 12
3 132 20 0.054 –
Tumor diameter (mm)
<20 176 1
≥20 125 31 <0.001 0.003
LNM, lymph node metastasis; FIGO, International Federation of 
Gynecology and Obstetrics.
1Only variables with a P < 0.05 at univariate analysis were included in 
multivariate analysis. Variables with a P < 0.05 were highlighted in bold
2Chi- squared test or Fisher exact test.
3Logistic regression analysis.
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preoperatively. In fact, MRI [25, 26] and transvaginal 
ultrasound [26, 27] show a very high diagnostic accuracy 
in measuring tumor volume. Moreover, tumor volume 
can also be evaluated intraoperatively at frozen section 
analysis.
Recently, consistent findings have been reported sug-
gesting that SLN detection and consequently LND can 
be safely omitted in T1 apparently N0 breast cancer patients 
[28, 29].
Our data strongly support the hypothesis that a similar 
perspective can be tested in VLR early- stage cervical cancer 
population, as identified in this study. The possibility to 
avoid even SLN detection in these patients may shorten 
and simplify cervical cancer surgery and histopathological 
examination, with a positive impact on patient benefit 
and costs. In such situation, primary tumor risk factors 
can be used for guiding adjuvant treatment. Moreover, 
leaving unaltered the lymphatic system might have another 
positive effect, thanks to the potential immunological 
surveillance of metastasis- free LNs proximal to the tumor 
[30, 31]. On the other hand although the clinical role of 
micrometastases is still far from being clarified, the risk 
of missing useful information avoiding ultrastaging of SLN 
biopsy cannot be denied.
Based on these considerations, we calculated two hypo-
thetical clinical scenarios in 100 patients with early cervical 
Figure 1. Progression- free survival (PFS) and overall survival (OS) in very low- risk group (VLRG) and no- VLRG patient population.
Figure 2. Distribution of lymphnodal assessment procedures in 100 patients with ECC and negative lymph nodal assessment at preoperative imaging. 
VLRG selection after SLN (A); VLRG selection before SLN (B). ECC, early cervical cancer; VLRG, very low- risk group; SLN, sentinel lymph node.
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cancer and negative lymph nodal assessment at preoperative 
imaging (Fig. 2). Figure 2A shows the case in which all 
women receive SLN staging. Here, eight patients with VLR 
factors among 25 with nonoptimal SLN mapping may 
safely avoid systematic LND. Figure 2B shows the case in 
which SLN is not performed in VLRG. Here, 31 VLR 
women do not receive any LN surgical procedure. In both 
cases, we obtain a significant reduction in the rate of 
LND performed, but the two approaches do differ in terms 
of lymph nodes (LFN) staging. In Figure 2A, the majority 
of patients (74/100) receive ultrastaging of bilateral SLNs, 
which also allows to detect lymph nodal micrometastases 
or Isolated tumor cells (ITC). Even if the benefit provided 
by the removal of such low- volume lymph nodal disease 
is not already proven, the diagnosis of micrometastases is 
associated with a reduction in OS [32]. This kind of 
approach does not interfere with the rate of ultrastaging 
procedures performed in a hypothetical group of 100 
women, but provides benefit in the subset of patients in 
which optimal SLN detection failed, avoiding unnecessary 
LND (n = 8). On the other hand, in Figure 2B, only 51 
of 100 women, instead of 74 receive ultrastaging, but 31 
instead of eight safely avoid any lymph nodal surgical 
procedure. In this picture, we cannot exclude that some 
of the recurrences we registered in the VLRG could be 
predicted by nodal micrometastasis that SLN ultrastaging 
is able to detect. In other words, avoiding SLN detection 
may decrease the chances to correctly stratify risk categories. 
On the other side, the approach Figure 2B may decrease 
operative time and surgical costs, a relevant issue if we 
consider that cervical cancer is a social problem especially 
in developing countries with few resources and health 
facilities, including means to perform SLN technology (i.e., 
technetium or indocianine) and ultrastaging. Internal 
Hospital policy guidelines or clinical trials should define 
which one of these approaches is to be preferred.
In conclusion, our data suggest that in VLR early- stage 
cervical cancer LND can be omitted when SLN is not 
detected. A prospective clinical trial is going to start in 
Italy comparing standard SLN protocol versus no LN 
assessment in this patient population.
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